Surmodics (NASDAQ:SRDX) dropped 5.8% after a report about the Federal Trade Commission's review of its planned sale to private equity firm GTCR. The staff of the FTC has some concerns about the $627 ...
Some results have been hidden because they may be inaccessible to you